<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/080DCEEA-D49A-41D8-990F-885493EAA33D"><gtr:id>080DCEEA-D49A-41D8-990F-885493EAA33D</gtr:id><gtr:name>C4X Discovery Limited</gtr:name><gtr:address><gtr:line1>UNIT 310 DUCIE HOUSE 
DUCIE STREET</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M1 2JW</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/080DCEEA-D49A-41D8-990F-885493EAA33D" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>080DCEEA-D49A-41D8-990F-885493EAA33D</gtr:id><gtr:name>C4X Discovery Limited</gtr:name><gtr:address><gtr:line1>UNIT 310 DUCIE HOUSE 
DUCIE STREET</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M1 2JW</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>59954.0</gtr:offerGrant><gtr:projectCost>99924.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6BAA32D3-0592-4662-8707-B8FF49287B99"><gtr:id>6BAA32D3-0592-4662-8707-B8FF49287B99</gtr:id><gtr:firstName>Unknown</gtr:firstName><gtr:otherNames>Unknown</gtr:otherNames><gtr:surname>Unknown</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=710672"><gtr:id>FA6A44D4-8C4B-4DFF-9E22-01C01FE7012C</gtr:id><gtr:title>C4X Discovery - Validation of GPR142 as a Target for Type II Diabetes</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Concept</gtr:grantCategory><gtr:grantReference>710672</gtr:grantReference><gtr:abstractText>Type-2 diabetes (T2D) affects over 340 million people worldwide, creating an enormous
healthcare and socio-economic burden. The GPR142 receptor has been recently suggested as a
potential new target for treating T2D with a key advantage: its activation results in insulin
secretion as desired but, unlike other targets, it does this only in the presence of high blood
sugar levels. Medicines that work through GPR142 should therefore provide marked health
benefits over existing T2D therapies, as they will avoid the life-threatening side effect of low
blood sugar levels. Moreover, GPR142-based medicines would be orally administered,
avoiding the problems caused by injection-based therapies. Poor patient complaince with
injectables results in many of the T2D disease symptoms and most of the healthcare and
financial burden on the NHS. GPR142-based medicines, if feasible, would therefore not only
substantially improve T2D sufferers? health but also reduce the cost burden on the NHS too.
This project aims to carry out vital studies to confirm if GPR142 is indeed the exciting new
target for T2D that it promises to be. Very encouraging preliminary literature reports show
beneficial effects in clinically relevant acute animal models but, because T2D is a chronic
disease, further validation work to assess the chronic effects of GPR142 control is vital to see
if it is suitable for safe, long term control. The aim of this project is to perform chronic target
validation studies and, if positive, thereby open up a new and better class of T2D medications.
If positive, C4X has a head-start in leading this new area, having already designed hit
molecules for GPR142 with excellent properties. Positive results would justify a subsequent
C4X drug development programme. In time, this would lead to the creation of a new,
convenient, safe and effective class of T2D medicines that would have an enormous positive
impact on long-term patient health and the economic burden associated with T2D.</gtr:abstractText><gtr:fund><gtr:end>2015-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2015-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>59954</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">710672</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>